Cerenis Therapeutics Aktie
| 4,08EUR | -0,11EUR | -2,51% |
WKN DE: A14QR9 / ISIN: FR0012616852
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 63 | 61 | 51 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,08 | 0,08 | 0,09 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 10 | 13 | 8 | 7 | 6 |
| Summe Anlagevermögen | 0 | 9 | 8 | 8 | 8 |
| Summe Aktiva | 10 | 22 | 16 | 15 | 13 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 4 | 11 | 9 | 7 | 6 |
| Summe Eigenkapital | 7 | 11 | 7 | 8 | 7 |
| Summe Passiva | 10 | 22 | 16 | 15 | 13 |
Adresse
| 33-43, avenue Georges Pompidou, 31130 Balma | |
| Telefon | +33 (5) 62-24-97-06 |
| Fax | +33 (5) 61-57-34-12 |
| Internet | http://www.abionyx.com |
Management
|
Christian Chavy
Independent Director |
|
Constance Keyserling
Director-Clinical Development & Operations |
|
Cyrille Tupin
Chief Executive Officer & Director |
|
Emmanuel Huynh
Chairman |
|
Emmanuel de Fougeroux
Director-Finance & Administration |
|
Karen Noël
Independent Director |
|
Laura A. Coruzzi
Independent Director |
|
Laurent Guerci
Chief Digital & Innovation Officer |
|
Olivier Martinez
Director |
|
Renee Benghozi
Director-Clinical Research |
|
Rob Scott
Chief Medical Officer, Head-Research & Development |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.